Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA ) 3.600 +0.140 (+4.05%) Streaming Delayed Price Updated: 3:52 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lisata Therapeutics, Inc. - Common Stock < Previous 1 2 Next > Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial June 13, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events May 28, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer May 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results May 13, 2024 Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the... Via TheNewswire.com Exposures Product Safety Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events May 08, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 May 02, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma April 23, 2024 Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma April 09, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events April 03, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma March 21, 2024 Achieves critical first step toward priority review voucher From Lisata Therapeutics, Inc. Via GlobeNewswire Life Science Virtual Investor Forum Presentations Now Available for Online Viewing March 08, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 March 05, 2024 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ March 04, 2024 From Virtual Investor Conferences Via GlobeNewswire Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update February 29, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time February 22, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at BIO CEO & Investor Conference February 20, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme January 17, 2024 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy January 04, 2024 LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma December 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Present at NobleCon19 Investor Conference November 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in November November 09, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 02, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time October 26, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide October 24, 2023 Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors... From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer October 17, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in Upcoming Conferences in October September 28, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Participation in InfoSec World 2023 September 20, 2023 Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors September 12, 2023 From Lisata Therapeutics, Inc. Via GlobeNewswire Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma September 06, 2023 Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met) From Lisata Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.